Virios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest Up 76.9% in March

Virios Therapeutics, Inc. (NASDAQ:VIRI) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 170,200 shares, a growth of 76.9% from the February 29th total of 96,200 shares. Based on an average daily volume of 370,900 shares, the days-to-cover ratio is presently 0.5 days.

Virios Therapeutics Price Performance

NASDAQ VIRI opened at $0.48 on Thursday. Virios Therapeutics has a 1 year low of $0.28 and a 1 year high of $2.42. The stock has a market capitalization of $9.32 million, a PE ratio of -1.73 and a beta of 1.82. The company’s 50 day simple moving average is $0.40 and its two-hundred day simple moving average is $0.61.

Virios Therapeutics (NASDAQ:VIRI) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. On average, research analysts anticipate that Virios Therapeutics will post -0.27 EPS for the current year.

Institutional Investors Weigh In On Virios Therapeutics

Large investors have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. lifted its position in shares of Virios Therapeutics by 576.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 109,196 shares of the company’s stock worth $26,000 after purchasing an additional 93,050 shares during the period. State Street Corp purchased a new stake in shares of Virios Therapeutics in the 2nd quarter worth about $45,000. Citadel Advisors LLC purchased a new stake in shares of Virios Therapeutics in the 2nd quarter worth about $46,000. Renaissance Technologies LLC lifted its position in shares of Virios Therapeutics by 33.3% in the 4th quarter. Renaissance Technologies LLC now owns 235,400 shares of the company’s stock worth $56,000 after purchasing an additional 58,800 shares during the period. Finally, Susquehanna International Group LLP lifted its position in shares of Virios Therapeutics by 343.3% in the 1st quarter. Susquehanna International Group LLP now owns 161,811 shares of the company’s stock worth $59,000 after purchasing an additional 125,311 shares during the period. Institutional investors own 9.05% of the company’s stock.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.